Mesoblast Expands Ryoncil Access to 100 Million in the U.S.

New York, Thursday, 17 April 2025.
Mesoblast’s Ryoncil now covers 104 million U.S. lives, strengthening its position in regenerative medicine. This expansion enhances access for patients with serious conditions, potentially boosting revenue.